BR112015019568A2 - Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo - Google Patents

Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo

Info

Publication number
BR112015019568A2
BR112015019568A2 BR112015019568A BR112015019568A BR112015019568A2 BR 112015019568 A2 BR112015019568 A2 BR 112015019568A2 BR 112015019568 A BR112015019568 A BR 112015019568A BR 112015019568 A BR112015019568 A BR 112015019568A BR 112015019568 A2 BR112015019568 A2 BR 112015019568A2
Authority
BR
Brazil
Prior art keywords
peptides
peptide
mpkekvflkiekmgrnirn
amino acid
acid residues
Prior art date
Application number
BR112015019568A
Other languages
English (en)
Inventor
Zhang Lijuan
Carmichael Robin
Original Assignee
Helix Biomedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helix Biomedix Inc filed Critical Helix Biomedix Inc
Publication of BR112015019568A2 publication Critical patent/BR112015019568A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Birds (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Insects & Arthropods (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

PEPTÍDEO ISOLADO, COMPOSIÇÃO COMPREENDENDO O MESMO E USO DO MESMO. Os peptídeos tendo quatro a seis resíduos de aminoácidos são descritos que possuem atividade biológica. Estes peptídeos constituem fragmentos curtos do peptídeo HB-107 (MPKEKVFLKIEKMGRNIRN), que em si é um fragmento da proteína antimicrobiana cecropina B, e exibem propriedades das células estimuladoras e migratórias. Os peptídeos da invenção compreendem quatro a seis resíduos de aminoácidos contíguos localizados entre a posição II e 16 de HBl07 (MPKEKVFLKIEKMGRNIRN), nomeadamente EKMGRN. Os peptídeos descritos compreendem um agente útil para o tratamento médico de feridas na pele, tal como de úlceras diabéticas. Os peptídeos são também eficazes na prevenção e inversão de danos da superfície da pele resultantes de vários machucados ambientais. Mais importante, os efeitos terapêuticos dos peptídeos manifestam em concentrações iguais ou superiores às do peptídeo HB-107, e, assim, representam um meio menos caros, mais versátil para o desenvolvimento de terapias eficazes. Métodos para a produção e uso destes peptídeos são também descritos.
BR112015019568A 2013-02-14 2014-01-21 Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo BR112015019568A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361764913P 2013-02-14 2013-02-14
PCT/US2014/012378 WO2014126681A1 (en) 2013-02-14 2014-01-21 Short bio-active peptides for promoting wound healing

Publications (1)

Publication Number Publication Date
BR112015019568A2 true BR112015019568A2 (pt) 2017-08-22

Family

ID=50069319

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015019568A BR112015019568A2 (pt) 2013-02-14 2014-01-21 Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo

Country Status (24)

Country Link
US (2) US9487558B2 (pt)
EP (1) EP2956155B1 (pt)
JP (1) JP6348126B2 (pt)
KR (1) KR101894829B1 (pt)
CN (1) CN105120884B (pt)
AR (1) AR094835A1 (pt)
AU (1) AU2014216730B2 (pt)
BR (1) BR112015019568A2 (pt)
CA (1) CA2898717C (pt)
CY (1) CY1119087T1 (pt)
DK (1) DK2956155T3 (pt)
ES (1) ES2633437T3 (pt)
HK (1) HK1212243A1 (pt)
HU (1) HUE033976T2 (pt)
MX (1) MX363955B (pt)
MY (1) MY173174A (pt)
NZ (1) NZ711281A (pt)
PL (1) PL2956155T3 (pt)
RU (1) RU2606753C1 (pt)
SG (1) SG11201505538QA (pt)
SI (1) SI2956155T1 (pt)
TW (1) TWI587867B (pt)
WO (1) WO2014126681A1 (pt)
ZA (1) ZA201505516B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3020342A1 (en) * 2016-04-08 2017-11-23 Cornell University A method to enhance wound healing using silk-derived protein
EP3312608B1 (en) * 2016-10-24 2019-10-02 Akribes Biomedical GmbH Methods for identifying a non-healing skin wound and for monitoring the healing of a skin wound
US10232009B1 (en) * 2017-09-29 2019-03-19 Pro Sunfun Biotech Research And Development Co., Ltd. Peptide for promoting wound healing, its composition and method of using the same
CN108586575B (zh) * 2018-04-11 2020-08-14 福建省中科生物股份有限公司 一种多肽及其皮肤修复功能的应用
CZ308845B6 (cs) * 2019-01-21 2021-07-07 Globetech Innovation S.R.O Farmaceutická směs topicky hojivých peptidových složek pro použití k topické léčbě kožních defektů a/nebo k topickému hojení ran
CN116407611A (zh) * 2021-12-29 2023-07-11 四川好医生攀西药业有限责任公司 一种多肽在制备预防或治疗皮肤损伤疾病产品上的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6360939A (ja) * 1986-08-29 1988-03-17 Shin Etsu Chem Co Ltd 抗菌物質
US5861478A (en) 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
DE3854476T2 (de) 1987-07-06 1996-04-04 Univ Louisiana State Inhibierung von eukaryotischen pathogenen und neoplasmen mit lytischen peptiden.
CA2947349A1 (en) * 2006-06-13 2007-12-21 Helix Biomedix Inc. Peptide fragments for inducing synthesis of extracellular matrix proteins
DK2125878T3 (da) * 2007-01-05 2013-05-27 Helix Biomedix Inc Korte bioaktive peptider til cellulær og immunologisk modulation
RU2447896C1 (ru) * 2010-11-15 2012-04-20 Общество с ограниченной ответственностью "Аллофарм" Антимикробное вещество
WO2013029011A2 (en) * 2011-08-25 2013-02-28 University Of Central Florida Research Foundation, Inc. Methods and compositions comprising a c-terminal bax peptide

Also Published As

Publication number Publication date
EP2956155B1 (en) 2017-04-19
US9487558B2 (en) 2016-11-08
JP6348126B2 (ja) 2018-06-27
CA2898717A1 (en) 2014-08-21
JP2016513107A (ja) 2016-05-12
US20170000848A1 (en) 2017-01-05
MX363955B (es) 2019-04-08
TW201446258A (zh) 2014-12-16
AU2014216730A1 (en) 2015-08-20
KR101894829B1 (ko) 2018-09-05
CA2898717C (en) 2019-01-08
CN105120884B (zh) 2017-08-29
TWI587867B (zh) 2017-06-21
US20150353605A1 (en) 2015-12-10
SG11201505538QA (en) 2015-08-28
EP2956155A1 (en) 2015-12-23
MX2015009404A (es) 2016-10-07
AR094835A1 (es) 2015-09-02
HUE033976T2 (en) 2018-02-28
SI2956155T1 (sl) 2017-10-30
CY1119087T1 (el) 2018-01-10
PL2956155T3 (pl) 2017-09-29
HK1212243A1 (en) 2016-06-10
DK2956155T3 (en) 2017-07-31
CN105120884A (zh) 2015-12-02
NZ711281A (en) 2017-12-22
RU2606753C1 (ru) 2017-01-10
MY173174A (en) 2020-01-02
ZA201505516B (en) 2016-10-26
KR20150116883A (ko) 2015-10-16
ES2633437T3 (es) 2017-09-21
WO2014126681A1 (en) 2014-08-21
AU2014216730B2 (en) 2015-12-17

Similar Documents

Publication Publication Date Title
BR112015019568A2 (pt) Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo
Haisma et al. LL-37-derived peptides eradicate multidrug-resistant Staphylococcus aureus from thermally wounded human skin equivalents
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
BR112019008975A2 (pt) variantes de superfície celular imunologicamente discerníveis para uso em terapia celular
BR112018014028A2 (pt) anticorpos monoclonais anti-cd47 humanizados, de camundongo ou quimérico
CY1117655T1 (el) Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων
BR112014016672A2 (pt) compostos de carbamato e sua preparação e uso
CY1116728T1 (el) Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
WO2016070166A3 (en) Messenger una molecules and uses thereof
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BR112015006828A8 (pt) composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
BR112012027055A2 (pt) agente estabilizante para proteínas farmacêuticas.
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
WO2017200659A3 (en) A method to enhance wound healing using silk-derived protein
BR112016018205A8 (pt) métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente
BRPI1010861A8 (pt) métodos para tratamento de dor, inflamação ou osteoartrite, pacote e formulação farmacêutica
BR112013019513A2 (pt) métodos para o tratamento de úlceras diabéticas do pé
MX2019001633A (es) Proteina derivada de la seda para el tratamiento de la inflamacion.
BRPI0720874C1 (pt) composições compreendendo peptídeos bioativos curtos para modulação celular e imunológica
BR112022003745A2 (pt) Proteínas de fusão terapêuticas
BR112022024033A2 (pt) Formulações e métodos para o tratamento de síndrome do desconforto respiratório agudo, asma, ou rinite alérgica
BR112016014601A2 (pt) Composição dermatológica, dispositivo aplicador e método para preparar uma composição dermatológica
BR112019001130A2 (pt) uso de lactama e composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: HELIX BIOMEDIX INC. (US)

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements